Ewing Sarcoma – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2020 To 2030

Indication name: Ewing Sarcoma

Ewing Sarcoma – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2020 To 2030 (Markets covered: US, Germany, France, Spain, United Kingdom, Italy, Japan & China)

Ewing sarcoma has also been called peripheral primitive neuroectodermal tumor is a type of tumor that forms from a certain kind of cell in bone or soft tissue. In Ewing sarcoma, the chromosomal areas involved are the long arms (q) of chromosome 11 and 22 (11q24-22q12). These pieces break off and trade places. In most cases, this results in the abnormal fusion of two genes, usually the EWS and FLI genes.

Ewing sarcoma is described as localized, metastatic, or recurrent.

Localized Ewing sarcoma- The cancer is found in the bone or soft tissue where it began and may have spread to nearby tissue, including nearby lymph nodes.

Metastatic Ewing sarcoma- The cancer has spread from the bone or soft tissue where it began to other parts of the body. In Ewing tumor of bone, the cancer most often spreads to the lung, other bones, and bone marrow.

Recurrent Ewing sarcoma- The cancer has recurred (come back) after it has been treated. The cancer may come back in the bone or soft tissue where it began or in another part of the body.

Epidemiology- According to Thelansis, the annual incidence of Ewing sarcoma is 2.93 children per 1,000,000. Approximately 200-250 children and adolescents in the United States are diagnosed with a tumor in the Ewing family of tumors each year. Two-thirds will be long-term survivors (more than five years).

Competitive landscape of Ewing Sarcoma includes country specific approved as well as pipeline therapies. Any asset/ product specific designation or review and Accelerated Approval are being tracked and supplemented with analyst commentary.

KOLs insights of Ewing Sarcoma across 8 MM market from center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm and Unmet needs.

Ewing Sarcoma Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard) which Data Inputs with sourcing, Market Event and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden and pricing scenario, Summary and Insights.

Read more: Ewing Sarcoma – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2020 To 2030

S. No     Asset     Company            Stage
1 CLR 131 Cellectar Biosciences, Inc. Phase 1
2 pemetrexed Eli Lilly and Company Phase 2
3 racotumomab Laboratorio Elea Phoenix S.A. Phase 1
4 Temozolomide Gradalis, Inc. Phase 2
5 SP-2577 Salarius Pharmaceuticals, LLC Phase 1
6 TK216 Oncternal Therapeutics, Inc Phase 1
7 Imatinib mesylate Novartis Pharmaceuticals Phase 2
8 Enoblituzumab MacroGenics Phase 1
9 Lipegfilgrastim Teva Pharmaceutical Industries Phase 1
10 TB-403 Oncurious NV Phase 1
Continued...